Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth

Cancer Cell

Volumn 3, Issue 1, 2003, Pages 75-88

  Mack, Fiona A ^a   Rathmell, W Kimryn ^a   Arsham, Andrew M ^a,b   Gnarra, James ^c   Keith, Brian ^a   Simon, M Celeste ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; PROTEIN SUBUNIT; UBIQUITIN; DNA BINDING PROTEIN; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIGASE; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE TARGETING; GENETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TERATOCARCINOMA; TUMOR CELL LINE; TUMOR GROWTH; VON HIPPEL LINDAU DISEASE; ANIMAL; APOPTOSIS; CELL CULTURE; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; VASCULARIZATION;

ANIMALIA; MURINAE;

ANIMALS; APOPTOSIS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HIPPEL-LINDAU DISEASE; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIGASES; MICE; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTEIN SUBUNITS; TERATOCARCINOMA; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0038383678     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00240-4     Document Type: Article

References (61)

1. Arany Z., Huang L.E., Eckner R., Bhattacharya S., Jiang C., Goldberg M.A., Bunn H.F., Livingston D.M. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA. 93:1996;12969-12973.
2. Arsham A.M., Plas D.R., Thompson C.B., Simon M.C. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J. Biol. Chem. 277:2002;15162-15170.
3. Bindra R.S., Vasselli J.R., Stearman R., Linehan W.M., Klausner R.D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62:2002;3014-3019.
4. Bonicalzi M.E., Groulx I., de Paulsen N., Lee S. Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 276:2001;1407-1416.
5. Bruick R.K. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA. 97:2000;9082-9087.
6. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 294:2001;1337-1340.
7. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:1998;485-490.
8. Carrero P., Okamoto K., Coumailleau P., O'Brien S., Tanaka H., Poellinger L. Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia-inducible factor 1alpha. Mol. Cell. Biol. 20:2000;402-415.
9. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., Maher E.R., Pugh C.W., Ratcliffe P.J., Maxwell P.H. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741.
10. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
11. Ebert B.L., Bunn H.F. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol. Cell. Biol. 18:1998;4089-4096.
12. Epstein A.C., Gleadle J.M., McNeill L.A., Hewitson K.S., O'Rourke J., Mole D.R., Mukherji M., Metzen E., Wilson M.I., Dhanda A., et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 107:2001;43-54.
13. Foster K., Prowse A., van den Berg A., Fleming S., Hulsbeek M.M., Crossey P.A., Richards F.M., Cairns P., Affara N.A., Ferguson-Smith M.A., et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3:1994;2169-2173.
14. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:1994;85-90.
15. Gnarra J.R., Duan D.R., Weng Y., Humphrey J.S., Chen D.Y., Lee S., Pause A., Dudley C.F., Latif F., Kuzmin I., et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim. Biophys. Acta. 1242:1996;201-210.
16. Gnarra J.R., Ward J.M., Porter F., Wagner J., Devor D., Grinberg A., Emmert-Buck M., Westphal H., Klausner R.D., Linehan W.M. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl. Acad. Sci. USA. 94:1997;9102-9107.
17. Groulx I., Lee S. Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 22:2002;5319-5336.
18. Gunawan B., Huber W., Holtrup M., von Heydebreck A., Efferth T., Poustka A., Ringert R.H., Jakse G., Fuzesi L. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma. gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis Cancer Res. 61:2001;7731-7738.
19. Haase V.H., Glickman J.N., Socolovsky M., Jaenisch R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA. 98:2001;1583-1588.
20. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
21. Hoffman M.A., Ohh M., Yang H., Klco J.M., Ivan M., Kaelin W.G. Jr. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Genet. 10:2001;1019-1027.
22. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., et al. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62:2002;2962-2970.
23. Ikeda E., Achen M.G., Breier G., Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270:1995;19761-19766.
24. Iliopoulos O., Kibel A., Gray S., Kaelin W.G. Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:1995;822-826.
25. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA. 93:1996;10595-10599.
26. Ivan M., Kondo K., Yang H., Kim W., Valiando J., Ohh M., Salic A., Asara J.M., Lane W.S., Kaelin W.G. Jr. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation. implications for O2 sensing Science. 292:2001;464-468.
27. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A.v., Hebestreit H.F., Mukherji M., Schofield C.J., et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:2001;468-472.
28. Jiang B.H., Zheng J.Z., Leung S.W., Roe P., Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J. Biol. Chem. 272:1997;19253-19260.
29. Kallio P.J., Wilson W.J., O'Brien S., Makino Y., Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:1999;6519-6525.
30. Kamada M., Suzuki K., Kato Y., Okuda H., Shuin T. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cell motility. Cancer Res. 61:2001;4184-4189.
31. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246.
32. Kozma L., Kiss I., Nagy A., Szakall S., Ember I. Investigation of c-myc and K-ras amplification in renal clear cell adenocarcinoma. Cancer Lett. 111:1997;127-131.
33. Krieg M., Haas R., Brauch H., Acker T., Flamme I., Plate K.H. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 19:2000;5435-5443.
34. Kung A.L., Wang S., Kico J.M., Kaelin W.G. Jr., Livingston D.M. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:2000;1335-1340.
35. Lando D., Peet D.J., Whelan D.A., Gorman J.J., Whitelaw M.L. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science. 295:2002;858-861.
36. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:1996;2746-2753. a.
37. Levy A.P., Levy N.S., Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271:1996;25492-25497. b.
38. Liang Y., Buettger C., Berner D.K., Matschinsky F.M. Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9). Diabetologia. 40:1997;1018-1027.
39. Lisztwan J., Imbert G., Wirbelauer C., Gstaiger M., Krek W. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13:1999;1822-1833.
40. Lonergan K.M., Iliopoulos O., Ohh M., Kamura T., Conway R.C., Conway J.W., Kaelin W.G. Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:1998;732-741.
41. Maher E.R., Kaelin W.G. Jr. von Hippel-Lindau disease. Medicine (Baltimore). 76:1997;381-391.
42. Maltepe E., Keith B., Arsham A.M., Brorson J.R., Simon M.C. The role of ARNT2 in tumor angiogenesis and the neural response to hypoxia. Biochem. Biophys. Res. Commun. 273:2000;231-238.
43. Maltepe E., Schmidt J.V., Baunoch D., Bradfield C.A., Simon M.C. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 386:1997;403-407.
44. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., Maxwell P.H. HIF activation identifies early lesions in VHL kidneys. evidence for site-specific tumor suppressor function in the nephron Cancer Cell. 1:2002;459-468.
45. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 1:2002;247-255.
46. Maxwell P.H., Dachs G.U., Gleadle J.M., Nicholls L.G., Harris A.L., Stratford I.J., Hakinson O., Pugh C.W., Ratcliffe P.J. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA. 94:1997;8104-8109.
47. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399:1999;271-275.
48. Mortensen R.M., Conner D.A., Chao S., Geisterfer-Lowrance A., Seidman J. Production of homozygous mutant ES cells with a single targeting construct. Mol. Cell. Biol. 12:1992;2391-2395.
49. Ohh M., Yauch R.L., Lonergan K.M., Whaley J.M., Stemmer-Rachamimov A.O., Louis D.N., Gavin B.J., Kley N., Kaelin W.G. Jr., Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1:1998;959-968.
50. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., Pavletich N., Chau V., Kaelin W.G. Jr. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2:2000;423-427.
51. Pause A., Lee S., Worrell R.A., Chen D.Y., Burgess W.H., Linehan W.M., Klausner R.D. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA. 94:1997;2156-2161.
52. Pause A., Lee S., Lonergan K.M., Klausner R.D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl. Acad. Sci. USA. 95:1998;993-998.
53. Pugh C.W., O'Rourke J.F., Nagao M., Gleadle J.M., Ratcliffe P.J. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J. Biol. Chem. 272:1997;11205-11214.
54. Reiter R.E., Anglard P., Liu S., Gnarra J.R., Linehan W.M. Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res. 53:1993;3092-3097.
55. Ryan H.E., Lo J., Johnson R.S. HIF-1a is required for solid tumor formation and embryonic vascularization. EMBO J. 17:1998;3005-3015.
56. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60:2000;4010-4015.
57. Sang N., Fang J., Srinivas V., Leshchinsky I., Caro J. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol. Cell. Biol. 22:2002;2984-2992.
58. Sowter H.M., Ratcliffe P.J., Watson P., Greenberg A.H., Harris A.L. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61:2001;6669-6673.
59. Stiles B., Gilman V., Khanzenson N., Lesche R., Li A., Qiao R., Liu X., Wu H. Essential role of AKT-1/protein kinase B alpha in PTEN-controlled tumorigenesis. Mol. Cell. Biol. 22:2002;3842-3851.
60. Tanimoto K., Makino Y., Pereira T., Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:2000;4298-4309.
61. Turner K.J., Moore J.W., Jones A., Taylor C.F., Cuthbert-Heavens D., Han C., Leek R.D., Gatter K.C., Maxwell P.H., Ratcliffe P.J., et al. Expression of hypoxia-inducible factors in human renal cancer. relationship to angiogenesis and to the von Hippel-Lindau gene mutation Cancer Res. 62:2002;2957-2961.